LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre Sells 4,399 Shares

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 4,399 shares of the business’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total transaction of $374,354.90. Following the sale, the chief executive officer now directly owns 1,827,003 shares in the company, valued at $155,477,955.30. The trade was a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $84.75 on Wednesday. The firm’s fifty day moving average is $84.27 and its 200-day moving average is $92.91. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The firm has a market cap of $1.91 billion, a P/E ratio of 46.31, a P/E/G ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm’s revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.44 earnings per share. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.94%. The ex-dividend date of this dividend is Thursday, May 15th. LeMaitre Vascular’s dividend payout ratio is presently 40.40%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on LMAT shares. Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.14.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of LMAT. Opal Wealth Advisors LLC bought a new position in LeMaitre Vascular during the first quarter worth $26,000. NBC Securities Inc. bought a new position in LeMaitre Vascular during the first quarter worth $36,000. Smartleaf Asset Management LLC boosted its stake in LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC boosted its stake in LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 117 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in LeMaitre Vascular during the first quarter worth $50,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.